Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells
However, its angiogenic properties raise legitimate safety considerations, suggesting that indication-specific developmentfavoring acute or localized applicationsmay be more appropriate than chronic systemic exposure
According to a published study on CJC-1295 growth hormone release, this pulsatile pattern closely mirrors endogenous GH secretion
Lower costs could broaden treatment uptake but they will not eliminate access challenges without supportive coverage and affordability programs, especially for underserved populations
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
